Autolus Therapeutics Announces Changes to its Board of Directors

-  Appointment of Elisabeth Leiderman, M.D. -  Resignation of Kapil Dhingra, M.D. LONDON, Dec. 22, 2023 -- Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing...

Related Keywords

London ,City Of ,United Kingdom ,Tel Aviv ,Israel ,Susana Noonan ,Elisabeth Leiderman ,Lauren Williams ,Kapil Dhingra ,Julia Wilson ,Corporate Governance Committee Of The Board ,Head Of Corporate Development For Decibel Therapeutics ,Wharton School ,Sa Noonan Communications ,Head Of Corporate Development At Fortress Biotech ,Astrazeneca ,University Of Pennsylvania ,Drug Administration ,Exchange Commission ,Complexa Inc ,Exchange Commission On ,Management Team ,Nasdaq ,American Medical Program Tel Aviv University ,Autolu Board ,Corporate Governance Committee ,Autolus Board ,Lis Leiderman ,Christian Itin ,Chief Executive Officer ,Biologics License Application ,B Cell Acute Lymphoblastic Leukemia ,Chief Financial Officer ,Chief Business Officer ,Corporate Development ,Decibel Therapeutics ,Senior Vice President ,Fortress Biotech ,Autolus Therapeutics ,Private Securities Litigation Reform Act ,Autolu Annual Report ,Markets ,